Add like
Add dislike
Add to saved papers

Micropapillary and Solid Histologic Patterns in N1 and N2 Lymph Node Metastases Are Independent Factors of Poor Prognosis in Patients with Stage II-III Lung Adenocarcinoma.

INTRODUCTION: High-grade histologic patterns are associated with poor prognosis in patients with primary nonmucinous lung adenocarcinoma (ADC). We investigated whether the presence of micropapillary and/or solid patterns (MIP/SOL) in lymph node (LN) metastases has prognostic value.

METHODS: Patients who underwent lobectomy for pathologic stage II-III lung ADC with N1 or N2 LN metastases (n=360; 2000-2012) were analyzed. We assessed overall survival (OS), lung cancer-specific cumulative incidence of death (LC-CID), and cumulative incidence of recurrence (CIR) between patients with and without MIP/SOL patterns in LN metastases. Multivariable Cox regression analysis was used to quantify the association between MIP/SOL patterns and outcomes.

RESULTS: Micropapillary and solid patterns in LN metastases were associated with a higher incidence of smoking history (p=0.004), tumor necrosis (p=0.013), and spread of tumor through air spaces (p<0.0001), a higher prevalence of micropapillary or solid pattern in the primary tumor (p<0.0001), shorter OS (5-year OS, 40% [95% CI, 29%-56%] vs. 63% [48-83%) for no MIP/SOL in LNs; p=0.03), higher LC-CID (5-year, 43% [29%-56%] vs. 14% (4-29%); p=0.013), and higher CIR (5-year, 65% [50%-77%] vs. 43% (25-60%); p=0.057). Micropapillary and solid patterns in LN metastases were independently associated with poor outcomes: OS (hazard ratio [HR], 1.81 [95% CI, 1.00-3.29]; p=0.05), LC-CID (HR, 3.10 [1.30-7.37]; p=0.01), and CIR (HR, 2.06 [1.09-3.90]; p=0.026).

CONCLUSION: MIP/SOL histological patterns in N1 or N2 LN metastases are associated with worse outcomes in patients with stage II-III lung ADC. MIP/SOL histological patterns in LN metastases can stratify patients with high-risk stage II-III lung ADC.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app